SCHEMBL1277360

SCHEMBL1277360

CC(=O)c1cccc(-c2ccccc2/C=C(\C)C(=O)NC(=N)N)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F10 P00742 2/20 0.40
BAZ2B Q9UIF8 1/20 0.39
BAZ2A Q9UIF9 1/20 0.39
HDAC2 Q92769 1/20 0.38
CHEK1 O14757 1/20 0.36
DHFR P00374 1/20 0.35
MAP4K4 O95819 1/20 0.35
CSNK1G2 P78368 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
MKNK2 Q9HBH9 1/20 0.35
MAP4K5 Q9Y4K4 1/20 0.35
NR1H4 Q96RI1 1/20 0.35
PRSS1 P07477 2/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
PARP1 P09874 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1277529 0.93 BAZ2B (0.44) F10BAZ2BBAZ2ACHEK1CSNK1G2
SCHEMBL1277606 0.92 NR1H4 (0.41) F10BAZ2BBAZ2ANR1H4PRSS1
SCHEMBL1277229 0.90 HDAC8 (0.45) F10BAZ2BBAZ2AHDAC2NR1H4
SCHEMBL1277762 0.90 ERN1 (0.42) F10NPC1RAB9A
SCHEMBL1277160 0.88 SMN1; SMN2 (0.41) F10HDAC2PRSS1KMT2ANPC1
SCHEMBL1277389 0.87 BAZ2B (0.38) F10BAZ2BBAZ2A
SCHEMBL1277284 0.84 KMT2A (0.35) F10KMT2AMEN1
SCHEMBL1277281 0.83 APP (0.43) F10PRSS1F2
SCHEMBL1277262 0.83 ADRA2C (0.39) F10CLK4
SCHEMBL1277133 0.82 F10 (0.37) F10PRSS1F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC (JP) 2012-04-12 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES AJINOMOTO CO., INC. (JP) 2011-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110082109-A1 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 F10 4727/4885BAZ2B 1648/4885BAZ2A 1311/4885
US-20120088737-A2 NOVEL ACYL GUANIDINE DERIVATIVES SLC9A3, NHERF1, SLC9A2 F10 4727/4885BAZ2B 1648/4885BAZ2A 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.